Absci to Participate in Upcoming Investor Conferences

ABSI 10.24.2024

Full Press ReleaseSEC FilingsOur ABSI Tweets

About Gravity Analytica

Recent News

  • 02.05.2025 - Guggenheim Securities SMID Cap Biotech Conference
  • 01.22.2025 - Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
  • 01.22.2025 - Gil Blum

Recent Filings

  • 01.15.2025 - EX-99.1 EX-99.1
  • 01.15.2025 - 8-K Current report
  • 01.10.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

  • Truist Securities BioPharma Symposium (New York, NY)Hosting 1x1 meetings on Thursday, November 7
  • Guggenheim Securities Inaugural Healthcare Innovation Conference (Boston, MA)Fireside chat on Monday, November 11 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings
  • UBS Global Healthcare Conference (Rancho Palos Verdes, CA)Fireside chat on Wednesday, November 13 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time, and hosting 1x1 meetings
  • Stifel 2024 Healthcare Conference (New York, NY)Fireside chat on Monday, November 18 at 1:50 p.m. Eastern Time / 10:50 a.m. Pacific Time, and hosting 1x1 meetings
  • Jefferies London Healthcare Conference (London, UK)Hosting 1x1 meetings on Tuesday, November 19 and Wednesday, November 20

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at:investors.absci.com.

About Absci

Absciis a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. OurIntegrated Drug CreationTM platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visitwww.absci.comand follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), andYouTube.

Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@absci.com

Media Contactpress@absci.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com